 |
52 Diseases |  |
1 Trial |
|
1 Trial |  |
298 News |  |
| «12345» |
- |||| luminespib (AUY922) / Ligand
Trial completion, Trial primary completion date, Metastases: A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy. (clinicaltrials.gov) - Apr 20, 2015
P2, N=152, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | Trial primary completion date: Nov 2014 --> Aug 2014
- |||| Piqray (alpelisib) / Novartis, Zykadia (ceritinib) / Novartis, Tabrecta (capmatinib) / Incyte, Novartis
Enrollment open, Metastases: A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Mar 12, 2015
P2, N=115, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | Trial primary completion date: Nov 2014 --> Aug 2014 Not yet recruiting --> Recruiting
- | luminespib (AUY922) / Ligand
Enrollment change, Stroma: Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor (clinicaltrials.gov) - Mar 7, 2015
P2, N=24, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
Not yet recruiting --> Recruiting N=34 --> 24
- luminespib (AUY922) / Ligand, sunitinib / Generic mfg.
Trial primary completion date, Stroma, Metastases: A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) Patients (clinicaltrials.gov) - Feb 26, 2015
P2, N=25, Recruiting, Sponsor: National Health Research Institutes, Taiwan
N=34 --> 24 Trial primary completion date: Oct 2014 --> May 2015
- | luminespib (AUY922) / Ligand
Enrollment closed, Trial primary completion date, Stroma: Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor (clinicaltrials.gov) - Feb 3, 2015
P2, N=34, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
Trial primary completion date: Oct 2014 --> May 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Jan 2016
- luminespib (AUY922) / Ligand, Erbitux (cetuximab) / Eli Lilly
Enrollment closed, Metastases: Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 8, 2015
P1, N=18, Active, not recruiting, Sponsor: Swedish Medical Center
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Jan 2016 Recruiting --> Active, not recruiting
- | luminespib (AUY922) / Ligand
Enrollment closed: HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET (clinicaltrials.gov) - Nov 14, 2014
P2, N=25, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| luminespib (AUY922) / Ligand
Enrollment closed, Enrollment change: An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations (clinicaltrials.gov) - Nov 5, 2014
P2, N=55, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=108 --> 55
- luminespib (AUY922) / Ligand
Trial primary completion date, EGFR exon 20: Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR (clinicaltrials.gov) - Nov 4, 2014
P2, N=29, Recruiting, Sponsor: Massachusetts General Hospital
Recruiting --> Active, not recruiting | N=108 --> 55 Trial primary completion date: Mar 2015 --> Mar 2016
- ||||| Piqray (alpelisib) / Novartis, Zykadia (ceritinib) / Novartis, Tabrecta (capmatinib) / Incyte, Novartis
New P2 trial, Metastases: A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Oct 27, 2014
P2, N=115, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- || Zykadia (ceritinib) / Novartis
Enrollment change, Trial primary completion date: Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer (clinicaltrials.gov) - Sep 28, 2014
P1, N=69, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Mar 2015 --> Mar 2016 N=142 --> 69 | Trial primary completion date: Dec 2014 --> Aug 2016
- luminespib (AUY922) / Ligand, Erbitux (cetuximab) / Eli Lilly
Trial primary completion date, Metastases: Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 19, 2014
P1, N=18, Recruiting, Sponsor: Swedish Medical Center
N=142 --> 69 | Trial primary completion date: Dec 2014 --> Aug 2016 Trial primary completion date: Feb 2014 --> Nov 2014
- | Piqray (alpelisib) / Novartis
Trial completion, Enrollment change, Combination therapy, Metastases: PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer (clinicaltrials.gov) - Sep 15, 2014
P1, N=18, Completed, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Feb 2014 --> Nov 2014 Recruiting --> Completed | N=41 --> 18
- luminespib (AUY922) / Ligand
Trial termination, Metastases: Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy (clinicaltrials.gov) - Jul 8, 2014
P2, N=15, Terminated, Sponsor: University Health Network, Toronto
Recruiting --> Completed | N=41 --> 18 Recruiting --> Terminated
- luminespib (AUY922) / Ligand
Enrollment change, Trial termination, Metastases: Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy (clinicaltrials.gov) - Jul 8, 2014
P2, N=15, Terminated, Sponsor: University Health Network, Toronto
Recruiting --> Terminated N=37 --> 15 | Recruiting --> Terminated
- | luminespib (AUY922) / Ligand
Trial completion, Metastases: A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jul 1, 2014
P1, N=23, Completed, Sponsor: SCRI Development Innovations, LLC
N=37 --> 15 | Recruiting --> Terminated Active, not recruiting --> Completed
- luminespib (AUY922) / Ligand, Herceptin (trastuzumab) / Roche
Trial primary completion date: Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab (clinicaltrials.gov) - Jun 26, 2014
P2, N=45, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Trial primary completion date: May 2014 --> Oct 2013
- luminespib (AUY922) / Ligand, Herceptin (trastuzumab) / Roche
Phase classification: Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab (clinicaltrials.gov) - Jun 26, 2014
P2, N=45, Completed, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: May 2014 --> Oct 2013 Phase classification: P1 --> P2
- | luminespib (AUY922) / Ligand, Herceptin (trastuzumab) / Roche
Trial completion, Phase classification, Trial primary completion date: Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab (clinicaltrials.gov) - Jun 26, 2014
P2, N=45, Completed, Sponsor: Novartis Pharmaceuticals
Phase classification: P1 --> P2 Active, not recruiting --> Completed | Phase classification: P1 --> P2 | Trial primary completion date: May 2014 --> Oct 2013
- | luminespib (AUY922) / Ligand
Enrollment closed: A Study of the HSP90 Inhibitor AUY922 (clinicaltrials.gov) - Jun 19, 2014
P2, N=42, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed | Phase classification: P1 --> P2 | Trial primary completion date: May 2014 --> Oct 2013 Recruiting --> Active, not recruiting
- luminespib (AUY922) / Ligand
Trial primary completion date: Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jun 2, 2014
P1/2, N=43, Active, not recruiting, Sponsor: Northwestern University
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2014 --> Dec 2015
- luminespib (AUY922) / Ligand
Enrollment open, Metastases: AUY922 in Patient With Stage IV NSCLC (clinicaltrials.gov) - Jun 2, 2014
P2, N=63, Recruiting, Sponsor: National Taiwan University Hospital
Trial primary completion date: Dec 2014 --> Dec 2015 Not yet recruiting --> Recruiting
- || luminespib (AUY922) / Ligand
Trial primary completion date, Metastases: A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy. (clinicaltrials.gov) - May 26, 2014
P2, N=153, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Trial primary completion date: Nov 2013 --> Nov 2014
- luminespib (AUY922) / Ligand
Enrollment open, Metastases: Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer (clinicaltrials.gov) - May 26, 2014
P1, N=38, Recruiting, Sponsor: Jonsson Comprehensive Cancer Center
Trial primary completion date: Nov 2013 --> Nov 2014 Not yet recruiting --> Recruiting
- luminespib (AUY922) / Ligand, Herceptin (trastuzumab) / Roche
Trial termination: Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients (clinicaltrials.gov) - Feb 19, 2014
P2, N=21, Terminated, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Completed --> Terminated
- || Zykadia (ceritinib) / Novartis
Enrollment change: Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer (clinicaltrials.gov) - Feb 17, 2014
P1, N=142, Recruiting, Sponsor: Novartis Pharmaceuticals
Completed --> Terminated N=65 --> 142
- luminespib (AUY922) / Ligand
Enrollment open, EGFR exon 20: Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR (clinicaltrials.gov) - Oct 6, 2013
P2, N=29, Recruiting, Sponsor: Massachusetts General Hospital
N=65 --> 142 Not yet recruiting --> Recruiting
- luminespib (AUY922) / Ligand, sunitinib / Generic mfg.
Trial initiation date, Stroma, Metastases: A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) Patients (clinicaltrials.gov) - Sep 13, 2013
P2, N=25, Recruiting, Sponsor: National Health Research Institutes, Taiwan
Not yet recruiting --> Recruiting Initiation date: Jul 2011 --> Oct 2011
- luminespib (AUY922) / Ligand, sunitinib / Generic mfg.
Enrollment open, Stroma, Metastases: A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) Patients (clinicaltrials.gov) - Sep 13, 2013
P2, N=25, Recruiting, Sponsor: National Health Research Institutes, Taiwan
Initiation date: Jul 2011 --> Oct 2011 Not yet recruiting --> Recruiting
- luminespib (AUY922) / Ligand
Trial initiation date, Metastases: Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer (clinicaltrials.gov) - Aug 21, 2013
P1, N=38, Not yet recruiting, Sponsor: Jonsson Comprehensive Cancer Center
Not yet recruiting --> Recruiting Initiation date: Mar 2013 --> Jan 2014
- | luminespib (AUY922) / Ligand
New P2 trial, Metastases: AUY922 in Patient With Stage IV NSCLC (clinicaltrials.gov) - Aug 12, 2013
P2, N=63, Not yet recruiting, Sponsor: National Taiwan University Hospital
- || Zykadia (ceritinib) / Novartis
Trial initiation date: Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer (clinicaltrials.gov) - Jul 25, 2013
P1, N=142, Recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Mar 2013 --> Jan 2014 Initiation date: Mar 2013 --> Jun 2013
- ||| Zykadia (ceritinib) / Novartis
Enrollment open: Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer (clinicaltrials.gov) - Jul 25, 2013
P1, N=142, Recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Mar 2013 --> Jun 2013 Not yet recruiting --> Recruiting
- luminespib (AUY922) / Ligand
Enrollment change, Metastases: A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jun 20, 2013
P1, N=23, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
Not yet recruiting --> Recruiting N=36 --> 23
- ||| luminespib (AUY922) / Ligand
Enrollment closed, Metastases: A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy. (clinicaltrials.gov) - May 15, 2013
P2, N=153, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=36 --> 23 Recruiting --> Active, not recruiting
- luminespib (AUY922) / Ligand
New P2 trial, EGFR exon 20: Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR (clinicaltrials.gov) - May 13, 2013
P2, N=29, Recruiting, Sponsor: Massachusetts General Hospital
- luminespib (AUY922) / Ligand, Herceptin (trastuzumab) / Roche
Enrollment change: AUY922: 89Zr-trastuzumab PET for Imaging the Effect of HSP90 Inhibition (clinicaltrials.gov) - May 12, 2013
P1, N=7, Completed, Sponsor: University Medical Centre Groningen
Recruiting --> Active, not recruiting N=11 --> 7
- luminespib (AUY922) / Ligand
Enrollment closed: Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (clinicaltrials.gov) - May 6, 2013
P1/2, N=43, Active, not recruiting, Sponsor: Northwestern University
N=11 --> 7 Recruiting --> Active, not recruiting
- | luminespib (AUY922) / Ligand
Enrollment open: HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET (clinicaltrials.gov) - Apr 17, 2013
P2, N=25, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting --> Active, not recruiting Suspended --> Recruiting
- | luminespib (AUY922) / Ligand
Trial termination, Metastases: Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer (clinicaltrials.gov) - Apr 4, 2013
P2, N=98, Terminated, Sponsor: Novartis Pharmaceuticals
Suspended --> Recruiting Completed --> Terminated
- luminespib (AUY922) / Ligand
Enrollment open, Metastases: AUY922 for Advanced ALK-positive NSCLC (clinicaltrials.gov) - Mar 31, 2013
P2, N=20, Recruiting, Sponsor: Massachusetts General Hospital
Completed --> Terminated Not yet recruiting --> Recruiting
- luminespib (AUY922) / Ligand
Trial termination, Metastases: Hsp90 Inhibitor AUY922 in Treating Older Patients With Advanced Solid Malignancies (clinicaltrials.gov) - Feb 5, 2013
P1, N=2, Terminated, Sponsor: Dale Shepard, MD, PhD
Not yet recruiting --> Recruiting Recruiting --> Terminated; Slow accrual
- luminespib (AUY922) / Ligand
Enrollment change, Metastases: Hsp90 Inhibitor AUY922 in Treating Older Patients With Advanced Solid Malignancies (clinicaltrials.gov) - Feb 5, 2013
P1, N=2, Terminated, Sponsor: Dale Shepard, MD, PhD
Recruiting --> Terminated; Slow accrual N=24 --> 2
- luminespib (AUY922) / Ligand
New P1 trial, Metastases: Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer (clinicaltrials.gov) - Feb 4, 2013
P1, N=38, Not yet recruiting, Sponsor: Jonsson Comprehensive Cancer Center
- luminespib (AUY922) / Ligand
Enrollment change, Metastases: Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer (clinicaltrials.gov) - Jan 29, 2013
P2, N=98, Terminated, Sponsor: Novartis Pharmaceuticals
N=24 --> 2 N=67 --> 98
- ||| Zykadia (ceritinib) / Novartis
New P1 trial: Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer (clinicaltrials.gov) - Jan 17, 2013
P1, N=142, Recruiting, Sponsor: Novartis Pharmaceuticals
- Piqray (alpelisib) / Novartis
Trial initiation date, Combination therapy, Metastases: PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer (clinicaltrials.gov) - Jan 15, 2013
P1, N=41, Recruiting, Sponsor: Novartis Pharmaceuticals
N=67 --> 98 Initiation date: Sep 2012 --> Dec 2012
- Piqray (alpelisib) / Novartis
Enrollment open, Combination therapy, Metastases: PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer (clinicaltrials.gov) - Jan 15, 2013
P1, N=41, Recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Sep 2012 --> Dec 2012 Not yet recruiting --> Recruiting
- luminespib (AUY922) / Ligand
New P2 trial, Metastases: AUY922 for Advanced ALK-positive NSCLC (clinicaltrials.gov) - Dec 6, 2012
P2, N=20, Recruiting, Sponsor: Massachusetts General Hospital
- | luminespib (AUY922) / Ligand
Trial completion, Metastases: Dose Escalation Study of AUY922 in Advanced Solid Malignancies in Japan (clinicaltrials.gov) - Oct 18, 2012
P1, N=37, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Completed